Initiates Coverage on NantHealth (NASDAQ:NH) began coverage on shares of NantHealth (NASDAQ:NHGet Rating) in a report issued on Sunday. The firm set a “hold” rating on the stock.

NantHealth Stock Down 7.9 %

NH stock opened at $0.45 on Friday. NantHealth has a twelve month low of $0.40 and a twelve month high of $1.91. The stock has a market cap of $51.65 million, a P/E ratio of -0.93 and a beta of 1.81. The business’s 50-day moving average price is $0.50 and its 200-day moving average price is $0.60.

NantHealth (NASDAQ:NHGet Rating) last posted its quarterly earnings results on Thursday, August 4th. The company reported ($0.11) EPS for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.02). The company had revenue of $16.50 million during the quarter.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. Goldman Sachs Group Inc. purchased a new position in NantHealth in the 2nd quarter worth approximately $36,000. Millennium Management LLC bought a new stake in NantHealth in the 2nd quarter worth approximately $110,000. Atria Wealth Solutions Inc. increased its stake in NantHealth by 117.7% in the 2nd quarter. Atria Wealth Solutions Inc. now owns 491,942 shares of the company’s stock worth $205,000 after acquiring an additional 265,949 shares during the last quarter. Hartline Investment Corp bought a new stake in NantHealth in the 2nd quarter worth approximately $65,000. Finally, Highbridge Capital Management LLC bought a new stake in NantHealth in the 1st quarter worth approximately $665,000. 4.67% of the stock is owned by hedge funds and other institutional investors.

About NantHealth

(Get Rating)

NantHealth, Inc, together with its subsidiaries, operates as a healthcare IT company in the United States, Canada, and the United Kingdom. It offers Eviti, a software-as-a-service (SaaS) based clinical decision support solution that centralizes clinical content and treatment cost data from Medicare reimbursements and treatment toxicity data; Eviti Connect, which utilizes the platform to offer pre-authorization automation that helps payers and providers navigate the complexities of cancer care; and Eviti Advisor product that allows physicians to access the Eviti platform's comprehensive library of evidence-based treatment standards and protocols to inform treatment decisions.

See Also

Receive News & Ratings for NantHealth Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NantHealth and related companies with's FREE daily email newsletter.